Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect
Release Notes Disease Lists/Categories
About
About MalaCards Datasets Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
SJS
MCID: SVR097
MIFTS: 70

Severe Cutaneous Adverse Reaction (SJS)

Categories: Genetic diseases, Rare diseases, Skin diseases
Data Licensing
For inquiries, contact:
[email protected]
Genes Variations Tissues Related diseases Publications Symptoms & Phenotypes Drugs
Sources

Aliases & Classifications for Severe Cutaneous Adverse Reaction

About this section

MalaCards integrated aliases for Severe Cutaneous Adverse Reaction:

Name: Severe Cutaneous Adverse Reaction 57 36 16
Stevens-Johnson Syndrome 57 11 19 42 58 75 73 28 53 43 14 16 71 33
Toxic Epidermal Necrolysis 57 19 42 58 73 53 5 16 71 33
Stevens-Johnson Syndrome Toxic Epidermal Necrolysis Spectrum 19 42 71
Susceptibility to Severe Cutaneous Adverse Reaction 28 5 38
Drug-Induced Stevens Johnson Syndrome 19 42 71
Stevens-Johnson Syndrome/toxic Epidermal Necrolysis 19 42
Lyell's Syndrome 42 75
Lyell Syndrome 58 33
Hypersensitivity Syndrome, Carbamazepine-Induced, Susceptibility to 57
Sjs/ten - [stevens-Johnson Syndrome and Toxic Epidermal Necrolysis] 33
Stevens-Johnson Syndrome/toxic Epidermal Necrolysis Spectrum 58
Susceptibility to Severe Cutaneous Adverse Reaction Ity to 19
Severe Cutaneous Adverse Reaction, Susceptibility to 57
Hypersensitivity Syndrome, Carbamazepine-Induced 57
Toxic Epidermal Necrolysis, Susceptibility to 57
Stevens-Johnson Syndrome, Susceptibility to 57
Mycoplasma-Induced Stevens Johnson Syndrome 42
Dermatostomatitis, Stevens Johnson Type 58
Dermatostomatitis Stevens Johnson Type 73
Severe Cutaneous Adverse Reactions 75
Ten - [toxic Epidermal Necrolysis] 33
Toxic Epidermolysis 58
Sjs/ten 19
Sjs-Ten 58
Sjs 73
Ten 73

Characteristics:


Prevelance:

Stevens-Johnson Syndrome/toxic Epidermal Necrolysis Spectrum: 1-9/1000000 (Taiwan, Province of China, Germany) 58

Age Of Onset:

Stevens-Johnson Syndrome/toxic Epidermal Necrolysis Spectrum: All ages 58
Toxic Epidermal Necrolysis: All ages 58
Stevens-Johnson Syndrome: All ages 58

Classifications:

MalaCards categories:
Global: Genetic diseases Rare diseases
Anatomical: Skin diseases
See all MalaCards categories (disease lists)
ICD10: 31 32
ICD11: 33
Orphanet: 58  
Rare skin diseases


External Ids:

Disease Ontology 11 DOID:0050426
OMIM® 57 608579
ICD9CM 34 695.13
MeSH 43 D013262
NCIt 49 C79484
SNOMED-CT 68 73442001
ICD10 31 L51.1 L51.2
MESH via Orphanet 44 D004816 D013262
ICD10 via Orphanet 32 L51.1 L51.2
UMLS via Orphanet 72 C0014518 C0038325
UMLS 71 C0014518 C0038325 C1274933 more
Sources

Summaries for Severe Cutaneous Adverse Reaction

About this section

MedlinePlus Genetics: 42 Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a severe skin reaction most often triggered by particular medications. Although Stevens-Johnson syndrome and toxic epidermal necrolysis were once thought to be separate conditions, they are now considered part of a continuum. Stevens-Johnson syndrome represents the less severe end of the disease spectrum, and toxic epidermal necrolysis represents the more severe end.SJS/TEN often begins with a fever and flu-like symptoms. Within a few days, the skin begins to blister and peel, forming very painful raw areas called erosions that resemble a severe hot-water burn. The skin erosions usually start on the face and chest before spreading to other parts of the body. In most affected individuals, the condition also damages the mucous membranes, including the lining of the mouth and the airways, which can cause trouble with swallowing and breathing. The painful blistering can also affect the urinary tract and genitals. SJS/TEN often affects the eyes as well, causing irritation and redness of the conjunctiva, which are the mucous membranes that protect the white part of the eye and line the eyelids, and damage to the clear front covering of the eye (the cornea).Severe damage to the skin and mucous membranes makes SJS/TEN a life-threatening disease. Because the skin normally acts as a protective barrier, extensive skin damage can lead to a dangerous loss of fluids and allow infections to develop. Serious complications can include pneumonia, overwhelming bacterial infections (sepsis), shock, multiple organ failure, and death. About 10 percent of people with Stevens-Johnson syndrome die from the disease, while the condition is fatal in up to 50 percent of those with toxic epidermal necrolysis.Among people who survive, long-term effects of SJS/TEN can include changes in skin coloring (pigmentation), dryness of the skin and mucous membranes (xerosis), excess sweating (hyperhidrosis), hair loss (alopecia), and abnormal growth or loss of the fingernails and toenails. Other long-term problems can include impaired taste, difficulty urinating, and genital abnormalities. A small percentage of affected individuals develop chronic dryness or inflammation of the eyes, which can lead to increased sensitivity to light (photophobia) and vision impairment.

MalaCards based summary: Severe Cutaneous Adverse Reaction, also known as stevens-johnson syndrome, is related to sjogren syndrome and viral infectious disease. An important gene associated with Severe Cutaneous Adverse Reaction is HLA-B (Major Histocompatibility Complex, Class I, B), and among its related pathways/superpathways are NF-kappaB Signaling and Apoptosis and Autophagy. The drugs Miconazole and Clotrimazole have been mentioned in the context of this disorder. Affiliated tissues include skin, eye and salivary gland, and related phenotypes are nausea and vomiting and dysphagia

GARD: 19 Stevens-Johnson syndrome/toxic epidermal necrolysis (SJS/TEN) is a very severe reaction, most commonly triggered by medications, that causes skin tissue to die (necrosis) and detach. The mucous membranes of the eyes, mouth, and/or genitals are also commonly affected. SJS and TEN previously were thought to be separate conditions, but they are now considered part of a disease spectrum. SJS is at the less severe end of the spectrum, and TEN is at the more severe end. It is considered SJS when skin detachment involves less than 10% of the body surface, and TEN when skin detachment involves more than 30% of the body surface. People with skin detachment involving 10-30% of the body surface are said to have "SJS/TEN overlap." All forms of SJS/TEN are a medical emergency that can be life-threatening. The first symptoms of SJS/TEN often include fever and flu-like symptoms (such as general ill feeling, body aches, and cough). Within about 1 to 3 days, a red or purplish rash forms, and then the skin begins to blister and peel, leading to "raw" areas of skin that are painful. This often starts on the face and then spreads to other parts of the body. The mucous membranes may also become involved during this time, which can lead to symptoms such as severe conjunctivitis (when the eyes are affected), trouble swallowing and breathing (when the mouth and airway are affected), and difficulty urinating and genital pain (when the genitals are affected). SJS/TEN often is triggered by certain medications including allopurinol, anti-epileptics, pain relievers, cancer therapies, or antibiotics (sometimes up to 2 weeks after stopping the medication). SJS/TEN can also be triggered by infections such as pneumonia, herpes virus, and hepatitis A. In many cases the cause cannot be identified. People that may be at increased risk to develop SJS/TEN include those with HIV, a weakened immune system, a personal or family history of the condition, and certain variations of a gene called HLA-B. There are no universal diagnostic criteria for SJS/TEN. Currently the diagnosis is based on the person's medical history and symptoms. People suspected of having SJS/TEN should be admitted to the hospital to confirm the diagnosis and assess severity.

Orphanet 58 Stevens-johnson syndrome: A limited form of Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum characterized by destruction and detachment of the skin epithelium, involving less than 10% of the body surface area, and mucous membranes. Onset usually occurs 4-28 days after administration of the causal medication and is most frequently associated with anticonvulsants, antibacterial sulfonamides, allopurinol, nevirapine, and oxicams (non-steroidal anti-inflammatory drugs), but many other medications have also been implicated. The disease is not induced by medication in 15% of cases. Histology is characterized by an epidermal necrolysis. Multiple disabling long-term sequelae (especially cutaneous, ocular and psychological) are frequent.

Toxic epidermal necrolysis: An extended form of Stevens-Johnson syndrome/toxic epidermal necrolysis spectrum characterized by destruction and detachment of the skin epithelium, involving 30% or more of the body surface area, and mucous membranes. Onset usually occurs 4-28 days after administration of the causal medication and is most frequently associated with anticonvulsants, antibacterial sulfonamides, allopurinol, nevirapine, and oxicams (non-steroidal anti-inflammatory drugs), but many other medications have also been implicated. The disease is not induced by medication in 15% of cases. Histology is characterized by an epidermal necrolysis. Multiple disabling long-term sequelae (especially cutaneous, ocular and psychological) are frequent.

Stevens-johnson syndrome/toxic epidermal necrolysis spectrum: A rare toxic dermatosis with clinical and histological features characterized by the destruction and detachment of the skin epithelium and mucous membranes.

UniProtKB/Swiss-Prot: 73 A rare blistering mucocutaneous disease that share clinical and histopathologic features with toxic epidermal necrolysis. Both disorders are characterized by high fever, malaise, and a rapidly developing blistering exanthema of macules and target-like lesions accompanied by mucosal involvement. Stevens-Johnson syndrome is a milder disease characterized by destruction and detachment of the skin epithelium and mucous membranes involving less than 10% of the body surface area. Ocular symptoms include ulcerative conjunctivitis, keratitis, iritis, uveitis and sometimes blindness. It can be caused by a severe adverse reaction to particular types of medication, although Mycoplasma infections may induce some cases.

Disease Ontology: 11 A skin disease that is characterized by ulceration of less than 10 percent of the surface area of the body. The disease is often precipitated by the use of medications, such as antibiotics or antiepileptics, or onset of infection.

Wikipedia 75 Lyell's syndrome: Toxic epidermal necrolysis (TEN) is a type of severe skin reaction. Together with Stevens-Johnson... more...

Severe cutaneous adverse reactions: Severe cutaneous adverse reactions are a group of potentially lethal adverse drug reactions that involve... more...

Stevens-johnson syndrome: Stevens-Johnson syndrome (SJS) is a type of severe skin reaction. Together with toxic epidermal... more...

More information from OMIM: 608579
Sources

Related Diseases for Severe Cutaneous Adverse Reaction

About this section

Diseases related to Severe Cutaneous Adverse Reaction via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 951)
# Related Disease Score Top Affiliating Genes
1 sjogren syndrome 32.1 HSPG2 GZMB FASLG FAS CCR6
2 viral infectious disease 31.5 HLA-B HLA-A GZMB FAS CD4 CCR6
3 dry eye syndrome 31.4 HSPG2 CD4 CCR6
4 drug allergy 31.3 HLA-B CYP3A4 CYP2C19 CD4
5 pneumocystosis 31.2 CD8A CD4 CCR6
6 lymphopenia 31.2 IKZF1 FASLG FAS CCR6
7 cellulitis 31.1 CD8A CD4 CCR6
8 pharyngitis 31.1 CD8A CD4 CCR6
9 psoriasis 31.1 TGM1 HLA-C HLA-B HLA-A CD4 CCR6
10 skin disease 31.0 TGM1 PRF1 HLA-C HLA-B HLA-A GZMB
11 oral candidiasis 31.0 CD8A CD4 CCR6
12 pancytopenia 31.0 PRF1 IKZF1 CD8A CD4
13 aphthous stomatitis 31.0 HLA-B CD8A CD4 CCR6
14 liver disease 31.0 PPIG FASLG FAS CYP3A4 CYP2D6 CYP2C19
15 leukemia, chronic myeloid 30.9 IKZF1 HLA-A GZMB CD8A CD4 CCR6
16 human cytomegalovirus infection 30.9 CD8A CD4 CCR6
17 fungal infectious disease 30.9 CD8A CD4 CCR6
18 alopecia areata 30.9 HLA-C HLA-B HLA-A GZMB FASLG
19 hemophagocytic lymphohistiocytosis 30.9 PRF1 GZMB CD8A CD4 CCR6
20 thrombocytopenia due to platelet alloimmunization 30.8 CD8A CD4 CCR6
21 interstitial nephritis 30.8 CD8A CD4 CCR6
22 thrombocytopenic purpura, autoimmune 30.8 CD8A CD4 CCR6
23 adult t-cell leukemia/lymphoma 30.8 CD8A CD4 CCR6
24 erythema multiforme 30.8 GZMB GNLY FASLG FAS
25 sarcoidosis 1 30.8 HLA-A CD8A CD4 CCR6
26 leukemia, acute lymphoblastic 30.8 IKZF1 HLA-B CYP3A4 CD8A CD4 CCR6
27 syphilis 30.7 HLA-C FAS CD8A CD4 CCR6
28 pfeiffer syndrome 30.7 PRF1 HLA-A CD8A CD4 CCR6
29 pars planitis 30.7 HLA-B HLA-A CCR6
30 spongiotic dermatitis 30.7 CD8A CD4 CCR6
31 severe covid-19 30.7 CD8A CD4 CCR6
32 pure red-cell aplasia 30.7 HLA-A CD8A CD4
33 t-cell acute lymphoblastic leukemia 30.7 IKZF1 FASLG FAS CD8A CD4 CCR6
34 chorioretinitis 30.7 CD8A CD4 CCR6
35 t-cell adult acute lymphocytic leukemia 30.7 CD8A CD4 CCR6
36 skin sarcoidosis 30.7 CD8A CD4 CCR6
37 angioimmunoblastic t-cell lymphoma 30.7 CD8A CD4 CCR6
38 cryptococcosis 30.7 CD8A CD4 CCR6
39 lymphoproliferative syndrome 30.6 PRF1 FASLG FAS CCR6
40 folliculitis 30.6 GNLY CD4 CCR6
41 multidrug-resistant tuberculosis 30.6 CYP3A4 CD8A CD4
42 blepharitis 30.6 CD8A CD4 CCR6
43 bacterial sepsis 30.6 CD8A CD4 CCR6
44 posterior uveitis 30.6 HLA-B HLA-A CD4 CCR6
45 viral meningitis 30.6 CD8A CD4 CCR6
46 bacterial pneumonia 30.6 CD8A CD4 CCR6
47 aplastic anemia 30.6 PRF1 HLA-A GZMB FASLG FAS CYP3A4
48 rubella 30.6 HLA-C HLA-B HLA-A
49 dengue disease 30.6 CD8A CD4 CCR6
50 graves' disease 30.6 HLA-B HLA-A FASLG FAS

Graphical network of the top 20 diseases related to Severe Cutaneous Adverse Reaction:



Diseases related to Severe Cutaneous Adverse Reaction
Sources

Symptoms & Phenotypes for Severe Cutaneous Adverse Reaction

About this section

Human phenotypes related to Severe Cutaneous Adverse Reaction:

58 30 (show top 50) (show all 98)
# Description HPO Frequency Orphanet Frequency HPO Source Accession
1 nausea and vomiting 58 30 Hallmark (90%) Very frequent (99-80%)
Occasional (29-5%)
 HP:0002017
2 dysphagia 58 30 Frequent (33%) Frequent (79-30%)
Very frequent (99-80%)
 HP:0002015
3 polydipsia 58 30 Hallmark (90%) Very frequent (99-80%)
 HP:0001959
4 fatigue 58 30 Hallmark (90%) Very frequent (99-80%)
Very frequent (99-80%)
Very frequent (99-80%)
 HP:0012378
5 fever 58 30 Hallmark (90%) Very frequent (99-80%)
Very frequent (99-80%)
 HP:0001945
6 thrombocytopenia 58 30 Occasional (7.5%) Occasional (29-5%)
Very frequent (99-80%)
 HP:0001873
7 erythema 58 30 Hallmark (90%) Very frequent (99-80%)
Very frequent (99-80%)
 HP:0010783
8 macule 58 30 Hallmark (90%) Very frequent (99-80%)
Very frequent (99-80%)
 HP:0012733
9 weight loss 58 30 Hallmark (90%) Very frequent (99-80%)
Very frequent (99-80%)
 HP:0001824
10 neutropenia 58 30 Hallmark (90%) Very frequent (99-80%)
Occasional (29-5%)
 HP:0001875
11 sepsis 58 30 Occasional (7.5%) Occasional (29-5%)
Very frequent (99-80%)
Very rare (<4-1%)
 HP:0100806
12 abnormal blistering of the skin 58 30 Hallmark (90%) Very frequent (99-80%)
Very frequent (99-80%)
Very frequent (99-80%)
 HP:0008066
13 diarrhea 58 30 Hallmark (90%) Very frequent (99-80%)
Occasional (29-5%)
 HP:0002014
14 acantholysis 58 30 Hallmark (90%) Very frequent (99-80%)
Very frequent (99-80%)
Frequent (79-30%)
 HP:0100792
15 conjunctival hyperemia 58 30 Hallmark (90%) Very frequent (99-80%)
 HP:0030953
16 recurrent respiratory infections 58 30 Occasional (7.5%) Occasional (29-5%)
Frequent (79-30%)
 HP:0002205
17 malabsorption 58 30 Frequent (33%) Frequent (79-30%)
 HP:0002024
18 anemia 58 30 Occasional (7.5%) Occasional (29-5%)
Frequent (79-30%)
Frequent (79-30%)
 HP:0001903
19 anxiety 58 30 Frequent (33%) Frequent (79-30%)
 HP:0000739
20 elevated hepatic transaminase 58 30 Occasional (7.5%) Occasional (29-5%)
Frequent (79-30%)
Frequent (79-30%)
 HP:0002910
21 atypical scarring of skin 58 30 Frequent (33%) Frequent (79-30%)
 HP:0000987
22 skin ulcer 58 30 Occasional (7.5%) Occasional (29-5%)
Frequent (79-30%)
 HP:0200042
23 abdominal pain 58 30 Occasional (7.5%) Occasional (29-5%)
Frequent (79-30%)
 HP:0002027
24 anorexia 58 30 Frequent (33%) Frequent (79-30%)
 HP:0002039
25 myalgia 58 30 Frequent (33%) Frequent (79-30%)
 HP:0003326
26 cough 58 30 Occasional (7.5%) Occasional (29-5%)
Frequent (79-30%)
Frequent (79-30%)
 HP:0012735
27 skin rash 58 30 Frequent (33%) Frequent (79-30%)
 HP:0000988
28 headache 58 30 Frequent (33%) Frequent (79-30%)
 HP:0002315
29 abnormality of neutrophils 58 30 Frequent (33%) Frequent (79-30%)
 HP:0001874
30 keratoconjunctivitis sicca 58 30 Frequent (33%) Frequent (79-30%)
 HP:0001097
31 dysuria 58 30 Occasional (7.5%) Occasional (29-5%)
Frequent (79-30%)
Occasional (29-5%)
 HP:0100518
32 respiratory distress 58 30 Occasional (7.5%) Occasional (29-5%)
Frequent (79-30%)
 HP:0002098
33 excessive salivation 58 30 Frequent (33%) Frequent (79-30%)
Frequent (79-30%)
 HP:0003781
34 oral-pharyngeal dysphagia 58 30 Frequent (33%) Frequent (79-30%)
 HP:0200136
35 rhinitis 58 30 Frequent (33%) Frequent (79-30%)
 HP:0012384
36 oral mucosal blisters 58 30 Frequent (33%) Frequent (79-30%)
 HP:0200097
37 hyperpigmentation of the skin 58 30 Frequent (33%) Frequent (79-30%)
 HP:0000953
38 genital blistering 58 30 Frequent (33%) Frequent (79-30%)
 HP:0031464
39 pharyngitis 58 30 Frequent (33%) Frequent (79-30%)
 HP:0025439
40 abnormal bronchus morphology 58 30 Frequent (33%) Frequent (79-30%)
 HP:0025426
41 depression 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0000716
42 sudden cardiac death 58 30 Occasional (7.5%) Occasional (29-5%)
Occasional (29-5%)
 HP:0001645
43 generalized abnormality of skin 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0011354
44 visual impairment 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0000505
45 photophobia 58 30 Occasional (7.5%) Occasional (29-5%)
Occasional (29-5%)
Occasional (29-5%)
 HP:0000613
46 renal insufficiency 58 30 Occasional (7.5%) Occasional (29-5%)
Occasional (29-5%)
 HP:0000083
47 myocardial infarction 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0001658
48 gastrointestinal inflammation 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0004386
49 hematuria 58 30 Occasional (7.5%) Occasional (29-5%)
 HP:0000790
50 abnormal myocardium morphology 58 30 Occasional (7.5%) Occasional (29-5%)
Occasional (29-5%)
 HP:0001637

Clinical features from OMIM®:

608579 (Updated 08-Dec-2022)

GenomeRNAi Phenotypes related to Severe Cutaneous Adverse Reaction according to GeneCards Suite gene sharing:

25 (show all 25)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Increased shRNA abundance (Z-score > 2) GR00366-A-104 10.7 CYP3A4
2 Increased shRNA abundance (Z-score > 2) GR00366-A-118 10.7 HLA-A HLA-B HLA-C
3 Increased shRNA abundance (Z-score > 2) GR00366-A-124 10.7 HLA-C
4 Increased shRNA abundance (Z-score > 2) GR00366-A-14 10.7 CD4
5 Increased shRNA abundance (Z-score > 2) GR00366-A-147 10.7 CD4
6 Increased shRNA abundance (Z-score > 2) GR00366-A-149 10.7 HLA-C
7 Increased shRNA abundance (Z-score > 2) GR00366-A-153 10.7 CYP3A4
8 Increased shRNA abundance (Z-score > 2) GR00366-A-156 10.7 PRF1
9 Increased shRNA abundance (Z-score > 2) GR00366-A-160 10.7 CD4
10 Increased shRNA abundance (Z-score > 2) GR00366-A-162 10.7 HLA-C
11 Increased shRNA abundance (Z-score > 2) GR00366-A-184 10.7 CYP3A4
12 Increased shRNA abundance (Z-score > 2) GR00366-A-185 10.7 CYP3A4
13 Increased shRNA abundance (Z-score > 2) GR00366-A-19 10.7 CD4
14 Increased shRNA abundance (Z-score > 2) GR00366-A-215 10.7 CYP3A4
15 Increased shRNA abundance (Z-score > 2) GR00366-A-32 10.7 CD4
16 Increased shRNA abundance (Z-score > 2) GR00366-A-35 10.7 CYP3A4
17 Increased shRNA abundance (Z-score > 2) GR00366-A-47 10.7 HLA-C
18 Increased shRNA abundance (Z-score > 2) GR00366-A-69 10.7 PRF1
19 Increased shRNA abundance (Z-score > 2) GR00366-A-7 10.7 CYP3A4
20 Increased shRNA abundance (Z-score > 2) GR00366-A-74 10.7 HLA-A HLA-B HLA-C
21 Increased shRNA abundance (Z-score > 2) GR00366-A-86 10.7 PRF1
22 Increased shRNA abundance (Z-score > 2) GR00366-A-93 10.7 HLA-C
23 no effect GR00402-S-1 10.15 CCR6 CD4 CD8A CYP2C19 CYP2C9 CYP2D6
24 no effect GR00402-S-2 10.15 CCR6 CD4 CYP2C19 CYP2C9 CYP3A4 FAS
25 Reduced mammosphere formation GR00396-S 9.5 CCR6 CYP2C9 FAS FASLG HLA-C HSPG2

MGI Mouse Phenotypes related to Severe Cutaneous Adverse Reaction:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 immune system MP:0005387 9.97 CCR6 CD4 CD8A CYP2D6 FAS FASLG
2 hematopoietic system MP:0005397 9.73 CCR6 CD4 CD8A FAS FASLG GZMB
3 integument MP:0010771 9.28 CD4 CD8A CYP2D6 FAS FASLG HSPG2
Sources

Drugs & Therapeutics for Severe Cutaneous Adverse Reaction

About this section

Drugs for Severe Cutaneous Adverse Reaction (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show all 43)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Miconazole Approved, Investigational, Vet_approved Phase 4 22916-47-8 4189
2
Clotrimazole Approved, Vet_approved Phase 4 23593-75-1 2812
3 Anti-Infective Agents Phase 4
4 Calcineurin Inhibitors Phase 4
5 Cyclosporins Phase 4
6 Antifungal Agents Phase 4
7 Immunosuppressive Agents Phase 4
8 Ophthalmic Solutions Phase 4
9
Lenograstim Approved, Investigational Phase 2, Phase 3 135968-09-1
10
Etanercept Approved, Investigational Phase 3 185243-69-0
11
Coal tar Approved Phase 3 8007-45-2
12 Immunoglobulins, Intravenous Phase 3
13 Immunoglobulins Phase 3
14 Antibodies Phase 3
15 gamma-Globulins Phase 3
16 Rho(D) Immune Globulin Phase 3
17 Immunologic Factors Phase 2, Phase 3
18 Pharmaceutical Solutions Phase 2, Phase 3
19 Adjuvants, Immunologic Phase 2, Phase 3
20 Anti-Inflammatory Agents, Non-Steroidal Phase 3
21 Analgesics, Non-Narcotic Phase 3
22 Analgesics Phase 3
23
Folic acid Approved, Nutraceutical, Vet_approved Phase 1, Phase 2 59-30-3 6037
24
Riboflavin Approved, Investigational, Nutraceutical, Vet_approved Phase 1, Phase 2 83-88-5 493570
25 Folate Phase 1, Phase 2
26 Vitamins Phase 1, Phase 2
27 Vitamin B9 Phase 1, Phase 2
28 Trace Elements Phase 1, Phase 2
29 Photosensitizing Agents Phase 1, Phase 2
30
Vitamin B2 Phase 1, Phase 2
31 Vitamin B Complex Phase 1, Phase 2
32 Micronutrients Phase 1, Phase 2
33
Benzocaine Approved, Investigational Phase 1 1994-09-7, 94-09-7 2337
34
Tannic acid Approved Phase 1 1401-55-4 16129878 16129778
35 Anesthetics Phase 1
36 Anesthetics, Local Phase 1
37
Allopurinol Approved 315-30-0 2094 135401907
38
Lidocaine Approved, Vet_approved 137-58-6 3676
39
Isotretinoin Approved, Investigational, Nutraceutical 302-79-4, 4759-48-2 5538 444795 5282379
40 Anti-Bacterial Agents
41 Proxymetacaine
42 Lubricant Eye Drops
43 Immunoglobulin A

Interventional clinical trials:

(show all 32)
# Name Status NCT ID Phase Drugs
1 Evaluation of G-CSF as a Treatment of Toxic Epidermal Necrolysis Unknown status NCT02739295 Phase 4 recombinant granulocyte - colony stimulating factor;NaCl 0.9%
2 Efficacy of 0.05% Cyclosporin Eye Drop in Stevens Johnson Syndrome Patient With Chronic Dry Eye Completed NCT01488396 Phase 4 0.05%cyclosporin eye drop
3 NPB-01(Intravenous Immunoglobulin) Therapy for Patients With Stevens-Johnson Syndrome/ Toxic Epidermal Necrolysis Unresponsive to Corticosteroids. Completed NCT01696500 Phase 3 Intravenous immunoglobulin
4 Autologous ex Vivo Conjunctival Epithelial Cell Expansion for Ocular Surface Completed NCT00346450 Phase 3
5 Evaluating the Therapeutic Efficacy of Filgrastim in Severe Bullous Drug Eruptions (Lyell and Stevens-Johnson Syndromes) Recruiting NCT04651439 Phase 2, Phase 3 Filgrastim;Placebo
6 NATIENS: A Phase III Randomized Double-Blinded Placebo Controlled Study to Determine the Optimal Management and Mechanisms of Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis Not yet recruiting NCT02987257 Phase 3 Harmonized supportive care;Cyclosporine 5 mg/kg bid days 0-14;Etanercept 50 mg sc day 0 and day 3
7 The Use of Riboflavin/Ultraviolet A Cross-linked Human Donor Corneas as Carriers for the Boston Keratoprosthesis Completed NCT01582880 Phase 1, Phase 2 Riboflavin
8 Phase IIa Multicenter Clinical Trial to Determine the Feasibility and Safety of the Use of Adipose-derived Mesenchymal Stem Cells (ASC) in the Treatment of Patients With Cicatricial Conjunctivitis Associated With Lyell's Syndrome, Stevens-Johnson Syndrome and Pemphigoid of the Mucous Membranes With Ocular Involvement. Recruiting NCT05520086 Phase 1, Phase 2 Single Dose;Double Dose
9 Mesenchymal Stromal Cells Treatment in Lyell Syndrome: A Pilot Phase 1-2 Open Trial Not yet recruiting NCT04711200 Phase 1, Phase 2 Adipose derived stromal cells intravenously injected
10 Palifermin Treatment of Toxic Epidermal Necrolysis Terminated NCT02037347 Phase 1, Phase 2 Palifermin
11 Infliximab Therapy to Improve Retention of the Boston Keratoprosthesis in Patients After Stevens Johnson Syndrome/ Toxic Epidermal Necrolysis Withdrawn NCT01256489 Phase 1, Phase 2 Infliximab
12 Topical Infliximab in Autoimmune Eyes With Keratoprosthesis Withdrawn NCT02126020 Phase 1, Phase 2 topical infliximab
13 Pilot Study Comparing Remicade (Infliximab) vs. Standard Care in the Treatment of Toxic Epidermal Necrolysis Withdrawn NCT00372723 Phase 2 Remicaide (infliximab)
14 A Randomized Placebo Controlled Split-body Double-blind Phase II Clinical Trial to Investigate the Safety and Efficacy of Clobetasol 0.05% Ointment for the Treatment of Toxic Epidermal Necrolysis (TEN) Withdrawn NCT02319616 Phase 1, Phase 2 Clobetasol 0.05% ointment;Placebo
15 Platelet Rich-plasma in Management of Chronic Multiple Oral Ulcers Completed NCT03878771 Phase 1 Dermovate cream in Orabase
16 Comparison of Corneal Epitheliotropic Factors in Autologous Serum Eye Drops Between Nonautoimmune Dry Eye and Stevens-Johnson Syndrome With Dry Eye Unknown status NCT01122303
17 A Prospective Study to Prove the Usefulness of HLA-B*5801 Screening Test for the Prevention of Allopurinol-induced Severe Cutaneous Adverse Reaction in Patient With Chronic Kidney Disease Unknown status NCT03046914
18 The Effects of Minor Salivary Gland Transplantation for Cicatrizing Conjunctivitis Unknown status NCT03839069
19 A Prospective Multicenter Cohort Study Assessing Outcomes in Stevens Johnsons Syndrome and Toxic Epidermal Necrolysis Unknown status NCT03585946 Site specific standard of care comparison
20 Evaluating the Effect of Isotretinoin in Regulatory T-cell Function in Adverse Cutaneous Drug Eruptions (ACDEs): A Pilot Study Unknown status NCT02795143 Isotretinoin
21 The Multicenter Registry of Patients With Severe Cutaneous Adverse Reactions Among Tertiary Medical Institutes in Thailand Unknown status NCT02574988
22 Drug Patch Tests, Enzyme-linked Immunosorbent Spot Assay (Elispot) and Lymphocyte Transformation Tests in Patients With Severe Cutaneous Adverse Reaction to Drugs (SCARs) Unknown status NCT03176342
23 Stevens-Johnson Syndrome Associated With Antimicrobial Completed NCT00844038
24 Salivary Gland and Labial Mucous Membrane Transplantation in the Treatment of Severe Symblepharon and Dry Eye in Patients With Stevens-Johnson Syndrome. Completed NCT01178242
25 Nutritional and Metabolic Characteristics of Critically Ill Patients Admitted for Severe Toxidermia Completed NCT05320653
26 A Prospective Open-label, Multicenter Clinical Investigation to Assess the Safety and Performance of ARGOS-IO System in Patients Undergoing Implantation of a Boston Keratoprosthesis (BKPro) Completed NCT02945176
27 An Evaluation of Tangible Boost Replenishing System for Patients With Stevens Johnson Syndrome, Sjogren's Syndrome, and Graft Versus Host Disease Recruiting NCT04313725
28 Meibomian Gland Probing in the Sub-Acute Phase of Patients With Stevens-Johnson Syndrome/Toxic Epidermal Necrolysis Recruiting NCT05145959
29 Adverse Cutaneous Drug Reactions Collection of Clinical Data and Biological Samples Recruiting NCT03659227
30 Increased Frequencies of Certain HLA Class II Alleles DRB1 and DQB1 in PV Patients Compared to Those in Healthy Donors Have Been Reported in Various Populations and Repeatedly Confirmed. Among the Russian Population, no Studies About the Association of PV and HLA Class II Genes Have Been Conducted. Thus, the Purpose of This Study Was to Investigate HLA Class II Alleles and Haplotypes in Russian Patients With Pemphigus Vulgaris. Recruiting NCT05284929
31 Association of Cytokines With the Development of Complications in Burn and Toxic Epidermal Necrolysis (TENS) Patients Recruiting NCT04252651
32 An Investigator-initiated Trial (IIT) on the Effect of Autologous Oral Mucosal Epithelial Sheet Transplantation in Corneal Limbal Deficiency Patients Available NCT02149732

Search NIH Clinical Center for Severe Cutaneous Adverse Reaction

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Severe Cutaneous Adverse Reaction cell therapies at LifeMap Discovery.
Stem-cell-based therapeutic approaches for Severe Cutaneous Adverse Reaction:
Cultivated corneal epithelial stem cells for treatment of ocular surface damage
Embryonic/Adult Cultured Cells Related to Severe Cutaneous Adverse Reaction:
Limbal corneal epithelial stem cells PMIDs: 23055668

Cochrane evidence based reviews: stevens-johnson syndrome

Sources

Genetic Tests for Severe Cutaneous Adverse Reaction

About this section

Genetic tests related to Severe Cutaneous Adverse Reaction:

# Genetic test Affiliating Genes
1 Susceptibility to Severe Cutaneous Adverse Reaction 28 HLA-A HLA-B
2 Stevens-Johnson Syndrome 28
Sources

Anatomical Context for Severe Cutaneous Adverse Reaction

About this section

Organs/tissues related to Severe Cutaneous Adverse Reaction:

MalaCards : Skin, Eye, Salivary Gland, Kidney, Lung, T Cells, Liver
Sources

Publications for Severe Cutaneous Adverse Reaction

About this section

Articles related to Severe Cutaneous Adverse Reaction:

(show top 50) (show all 6653)
# Title Authors PMID Year
1
HLA-A 31:01 and HLA-B 15:02 as genetic markers for carbamazepine hypersensitivity in children. 62 57 5
23588310 2013
2
Carbamazepine-induced toxic effects and HLA-B*1502 screening in Taiwan. 62 57 5
21428768 2011
3
Genetic susceptibility to carbamazepine-induced cutaneous adverse drug reactions. 62 57 5
16538176 2006
4
HLA-B*5801 allele as a genetic marker for severe cutaneous adverse reactions caused by allopurinol. 62 57 5
15743917 2005
5
Medical genetics: a marker for Stevens-Johnson syndrome. 62 57 5
15057820 2004
6
The spectrum of Stevens-Johnson syndrome and toxic epidermal necrolysis: a clinical classification. 62 57 5
8006430 1994
7
Inhibition of toxic epidermal necrolysis by blockade of CD95 with human intravenous immunoglobulin. 53 62 57
9774279 1998
8
HLA-A*3101 and carbamazepine-induced hypersensitivity reactions in Europeans. 62 57
21428769 2011
9
Granulysin is a key mediator for disseminated keratinocyte death in Stevens-Johnson syndrome and toxic epidermal necrolysis. 62 57
19029983 2008
10
Strong association between HLA-A*0206 and Stevens-Johnson syndrome in the Japanese. 62 57
17258541 2007
11
A marker for Stevens-Johnson syndrome ...: ethnicity matters. 62 57
16415921 2006
12
Risk of Stevens-Johnson syndrome and toxic epidermal necrolysis during first weeks of antiepileptic therapy: a case-control study. Study Group of the International Case Control Study on Severe Cutaneous Adverse Reactions. 62 57
10392983 1999
13
Medication use and the risk of Stevens-Johnson syndrome or toxic epidermal necrolysis. 62 57
7477195 1995
14
Clinical classification of cases of toxic epidermal necrolysis, Stevens-Johnson syndrome, and erythema multiforme. 62 57
8420497 1993
15
Genetic susceptibility to toxic epidermal necrolysis. 62 57
3477129 1987
16
Etiologic factors of the Stevens-Johnson syndrome. 62 57
7375977 1980
17
Underexpression and overexpression of Fas and Fas ligand: a double-edged sword. 53 62
20408337 2010
18
Fas ligand-induced proinflammatory transcriptional responses in reconstructed human epidermis. Recruitment of the epidermal growth factor receptor and activation of MAP kinases. 53 62
17977827 2008
19
[Type IV of hypersensitivity and its subtypes]. 53 62
18409354 2007
20
Serum levels of the Th1 promoter IL-12 and the Th2 chemokine TARC are elevated in erythema multiforme and Stevens-Johnson syndrome/toxic epidermal necrolysis and correlate with soluble Fas ligand expression. An immunoenzymatic study from the Italian Group of Immunopathology. 53 62
17460400 2007
21
Phenotypic diversity in delayed drug hypersensitivity: an immunologic explanation. 53 62
17008937 2006
22
Serious skin reactions and selective COX-2 inhibitors: a case series from prescription-event monitoring in England. 53 62
16872242 2006
23
Clinical heterogeneity of drug hypersensitivity. 53 62
15767024 2005
24
Evaluation of the potential role of cytokines in toxic epidermal necrolysis. 53 62
15482470 2004
25
Abnormal protein profiles in tears with dry eye syndrome. 53 62
12888052 2003
26
Toxic epidermal necrolysis and Stevens-Johnson syndrome are induced by soluble Fas ligand. 53 62
12707034 2003
27
Intracellular localization of keratinocyte Fas ligand explains lack of cytolytic activity under physiological conditions. 53 62
12473659 2003
28
Protein-based therapeutic approaches targeting death receptors. 53 62
12655300 2003
29
Delayed reactions to drugs show levels of perforin, granzyme B, and Fas-L to be related to disease severity. 53 62
11799383 2002
30
Fas-mediated cell death in toxic epidermal necrolysis and graft-versus-host disease: potential for therapeutic inhibition. 53 62
11103436 2000
31
Death receptors in cutaneous biology and disease. 53 62
10951228 2000
32
[Erythema multiforme. A heterogeneous pathologic phenotype]. 53 62
10434539 1999
33
Epithelial hyperproliferation and transglutaminase 1 gene expression in Stevens-Johnson syndrome conjunctiva. 53 62
10027391 1999
34
Safety profile of nevirapine, a nonnucleoside reverse transcriptase inhibitor for the treatment of human immunodeficiency virus infection. 53 62
9916603 1998
35
Microbial Keratitis in Patients With Stevens-Johnson Syndrome and Toxic Epidermal Necrolysis: Experience From a Tertiary Centre in Taiwan. 62
35587449 2023
36
Development of label-free electrochemical impedance spectroscopy for the detection of HLA-B*15:02 and HLA-B*15:21 for the prevention of carbamazepine-induced Stevens-Johnson syndrome. 62
36191668 2022
37
Enfortumab Vedotin-Associated Toxic Epidermal Necrolysis-like Toxic Erythema of Chemotherapy. 62
35925560 2022
38
[Bullous drug reaction after pembrolizumab administration: two case reports]. 62
35925211 2022
39
Intravenous immunoglobulins, cyclosporine and best supportive care in Epidermal Necrolysis: Diverse effects on systemic inflammation. 62
36463488 2022
40
Severe cicatricial entropion repair using mucous membrane graft in Stevens-Johnson syndrome. 62
36453379 2022
41
A case report involving suppressed nuclear receptor transcription factors 4a1 and Stevens-Johnson syndrome induced by a single dose of pembrolizumab and successfully treated with early steroid administration, resulting in complete remission of stage III lung cancer. 62
36464708 2022
42
Immunohistological analysis of pathogenic infiltrates in the epidermis and liver of a patient with toxic epidermal necrolysis accompanied by vanishing bile duct syndrome. 62
36176039 2022
43
Management of Toxic epidermal necrolysis Using Early Combination Therapy of intravenous immunoglobulin and Amniotic Membrane Grafting: A Case Report. 62
36455871 2022
44
A case of eruptive lichen spinulosus after toxic epidermal necrolysis. 62
36456468 2022
45
Associations of HLA and drug-metabolizing enzyme genes in co-trimoxazole-induced severe cutaneous adverse reactions. 62
36379177 2022
46
Immunomodulatory Treatment of Lyell's Syndrome: A Simultaneous Plasmapheresis and Intravenous Immunoglobulins Therapy. 62
35396849 2022
47
Pneumonia caused by toxic epidermal necrolysis. 62
36204458 2022
48
Treatment of toxic epidermal necrolysis and concurrent COVID-19-associated hyperinflammatory syndrome with systemic corticosteroids and etanercept. 62
36160836 2022
49
Toxic epidermal necrolysis in adult patients: Experience from the West Australian Collaboration. 62
35904488 2022
50
Toxic epidermal necrolysis-like acute graft-versus-host disease in pediatric bone marrow transplant patients: Case series and review of the literature. 62
35730149 2022
Sources

Variations for Severe Cutaneous Adverse Reaction

About this section

ClinVar genetic disease variations for Severe Cutaneous Adverse Reaction:

5
# Gene Name Type Significance ClinVarId dbSNP ID Position
1 HLA-B HLA-B*15:02 VAR Risk Factor
Risk Factor
 14909 GRCh37:
GRCh38:
2 HLA-B HLA-B, HLA-B*5801 VAR Risk Factor
Risk Factor
 14911 GRCh37:
GRCh38:
3 HLA-A NM_002116.8(HLA-A):c.776del (p.Pro259fs) DEL Not Provided
 441023 rs1554115495 GRCh37: 6:29912054-29912054
GRCh38: 6:29944277-29944277
Sources

Expression for Severe Cutaneous Adverse Reaction

About this section
Search GEO for disease gene expression data for Severe Cutaneous Adverse Reaction.
Sources

Pathways for Severe Cutaneous Adverse Reaction

About this section

Pathways related to Severe Cutaneous Adverse Reaction according to GeneCards Suite gene sharing:

(show all 27)
# Super pathways Score Top Affiliating Genes
1
NF-kappaB Signaling 3
12.47 IKZF1 GZMB FASLG FAS CD8A
2
Apoptosis and Autophagy 3
Show member pathways
 12.27 PRF1 GZMB FASLG FAS
3
Apoptosis and survival FAS signaling cascades 22
Show member pathways
 12.25 PRF1 GZMB FASLG FAS
4
Imipramine/Desipramine Pathway, Pharmacokinetics 60
Show member pathways
 12.09 CYP2C19 CYP2C9 CYP2D6 CYP3A4
5
Statin Pathway - Generalized, Pharmacokinetics 60
Show member pathways
 12.05 CYP3A4 CYP2D6 CYP2C9 CYP2C19
6
Immunoregulatory interactions between a Lymphoid and a non-Lymphoid cell 66
11.95 HLA-C HLA-B HLA-A CD8A
7
Biosynthesis of specialized proresolving mediators (SPMs) 66
Show member pathways
 11.76 CYP3A4 CYP2D6 CYP2C9
8
IL12-mediated signaling events 61
Show member pathways
 11.76 HLA-A GZMB FASLG CD8A CD4
9
Dendritic Cells Developmental Lineage Pathway 65
11.67 IKZF1 CD8A CD4
10
Constitutive androstane receptor pathway 74
Show member pathways
 11.61 CYP3A4 CYP2C9 CYP2C19
11
Ponatinib Pathway, Pharmacokinetics/Pharmacodynamics 60
Show member pathways
 11.58 CYP3A4 CYP2D6 CYP2C9
12
Allograft rejection 74
11.53 PRF1 HLA-C HLA-B HLA-A GZMB GNLY
13
Androstenedione and testosterone biosynthesis and metabolism p.1 22
Show member pathways
 11.51 CYP3A4 CYP2C9 CYP2C19
14
Platelet Aggregation Inhibitor Pathway, Pharmacodynamics 60
11.47 CYP3A4 CYP2C9 CYP2C19
15
Innate Lymphoid Cells Differentiation 65
11.46 IKZF1 GZMB CD8A CD4 CCR6
16
Retinol metabolism (TR) 22
Show member pathways
 11.41 CYP3A4 CYP2D6 CYP2C9 CYP2C19
17
Vortioxetine Pathway, Pharmacokinetics 60
Show member pathways
 11.37 CYP3A4 CYP2D6 CYP2C9 CYP2C19
18
Tamoxifen metabolism 74
Show member pathways
 11.33 CYP3A4 CYP2D6 CYP2C9 CYP2C19
19
IL-15 Signaling and its Primary Biological Effects in Different Immune Cell Types 65
Show member pathways
 11.28 GZMB FASLG FAS
20
Erlotinib Pathway, Pharmacokinetics 60
Show member pathways
 11.27 CYP3A4 CYP2D6 CYP2C9
21
Methadone Pathway, Pharmacokinetics 60
Show member pathways
 11.27 CYP3A4 CYP2D6 CYP2C9 CYP2C19
22
Antigen Presentation: Folding, assembly and peptide loading of class I MHC 66
11.15 HLA-C HLA-B HLA-A
23
Pazopanib Pathway, Pharmacokinetics 60
Show member pathways
 11.09 CYP2C19 CYP2C9 CYP2D6 CYP3A4
24
Cannabinoid receptor signaling 74
Show member pathways
 10.99 CYP3A4 CYP2C9 CYP2C19
25
Venlafaxine Pathway, Pharmacokinetics 60
Show member pathways
 10.88 CYP3A4 CYP2D6 CYP2C19
26
Metabolism of tetrahydrocannabinol (THC) 74
Show member pathways
 10.75 CYP3A4 CYP2C9
27
CTL Mediated Apoptosis 64
10.75 PRF1 HLA-C HLA-B HLA-A GZMB FASLG
Sources

GO Terms for Severe Cutaneous Adverse Reaction

About this section

Cellular components related to Severe Cutaneous Adverse Reaction according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 plasma membrane GO:0005887 10.34 CCR6 CD4 CD8A FASLG HLA-A HLA-B
2 plasma membrane GO:0005886 10.34 CCR6 CD4 CD8A FASLG HLA-A HLA-B
3 endoplasmic reticulum membrane GO:0005789 10.27 HLA-C HLA-B HLA-A CYP3A4 CYP2D6 CYP2C9
4 cell surface GO:0009986 10.03 HLA-C HLA-B HLA-A FASLG FAS CD4
5 cytolytic granule GO:0044194 9.43 PRF1 GZMB GNLY
6 obsolete integral component of lumenal side of endoplasmic reticulum membrane GO:0071556 9.33 HLA-C HLA-B HLA-A
7 MHC class I protein complex GO:0042612 9.1 HLA-C HLA-B HLA-A

Biological processes related to Severe Cutaneous Adverse Reaction according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 xenobiotic metabolic process GO:0006805 10.14 CYP3A4 CYP2D6 CYP2C9 CYP2C19
2 immune response GO:0006955 10.13 CCR6 CD4 CD8A FAS FASLG HLA-A
3 steroid metabolic process GO:0008202 10.1 CYP3A4 CYP2D6 CYP2C9 CYP2C19
4 cellular defense response GO:0006968 10.03 PRF1 GNLY CCR6
5 estrogen metabolic process GO:0008210 10 CYP3A4 CYP2D6 CYP2C9
6 long-chain fatty acid biosynthetic process GO:0042759 9.95 CYP3A4 CYP2D6 CYP2C9
7 organic acid metabolic process GO:0006082 9.93 CYP2D6 CYP2C9 CYP2C19
8 oxidative demethylation GO:0070989 9.91 CYP2C9 CYP2D6 CYP3A4
9 protection from natural killer cell mediated cytotoxicity GO:0042270 9.85 HLA-B HLA-A
10 heterocycle metabolic process GO:0046483 9.85 CYP3A4 CYP2D6 CYP2C19
11 alkaloid catabolic process GO:0009822 9.81 CYP2D6 CYP3A4
12 antigen processing and presentation GO:0019882 9.72 HLA-C HLA-B HLA-A CD8A
13 antigen processing and presentation of endogenous peptide antigen via MHC class I via ER pathway, TAP-independent GO:0002486 9.63 HLA-C HLA-B HLA-A
14 antigen processing and presentation of peptide antigen via MHC class I GO:0002474 9.58 HLA-C HLA-B HLA-A
15 xenobiotic catabolic process GO:0042178 9.56 CYP3A4 CYP2D6 CYP2C9 CYP2C19
16 monoterpenoid metabolic process GO:0016098 9.23 CYP3A4 CYP2D6 CYP2C9 CYP2C19

Molecular functions related to Severe Cutaneous Adverse Reaction according to GeneCards Suite gene sharing:

(show all 16)
# Name GO ID Score Top Affiliating Genes
1 heme binding GO:0020037 10.16 CYP3A4 CYP2D6 CYP2C9 CYP2C19
2 iron ion binding GO:0005506 10.15 CYP3A4 CYP2D6 CYP2C9 CYP2C19
3 peptide antigen binding GO:0042605 10.01 HLA-C HLA-B HLA-A
4 aromatase activity GO:0070330 9.93 CYP3A4 CYP2C9 CYP2C19
5 monooxygenase activity GO:0004497 9.92 CYP3A4 CYP2D6 CYP2C9 CYP2C19
6 caffeine oxidase activity GO:0034875 9.83 CYP2C9 CYP3A4
7 anandamide 14,15 epoxidase activity GO:0062189 9.81 CYP2D6 CYP3A4
8 anandamide 11,12 epoxidase activity GO:0062188 9.8 CYP3A4 CYP2D6
9 anandamide 8,9 epoxidase activity GO:0062187 9.78 CYP3A4 CYP2D6
10 steroid hydroxylase activity GO:0008395 9.76 CYP3A4 CYP2D6 CYP2C9 CYP2C19
11 (S)-limonene 6-monooxygenase activity GO:0018675 9.73 CYP2C19 CYP2C9
12 (S)-limonene 7-monooxygenase activity GO:0018676 9.71 CYP2C19 CYP2C9
13 (R)-limonene 6-monooxygenase activity GO:0052741 9.67 CYP2C19 CYP2C9
14 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen GO:0016705 9.56 CYP3A4 CYP2D6 CYP2C9 CYP2C19
15 oxidoreductase activity, acting on paired donors, with incorporation or reduction of molecular oxygen, reduced flavin or flavoprotein as one donor, and incorporation of one atom of oxygen GO:0016712 9.5 CYP3A4 CYP2D6 CYP2C9 CYP2C19
16 TAP binding GO:0046977 9.1 HLA-C HLA-B HLA-A
Sources

Sources for Severe Cutaneous Adverse Reaction

About this section
2 CDC
6 CNVD
8 Cosmic
9 dbSNP
10 DGIdb
16 EFO
17 ExPASy
18 FMA
19 GARD
27 GO
28 GTR
29 HMDB
30 HPO
31 ICD10
32 ICD10 via Orphanet
33 ICD11
34 ICD9CM
35 IUPHAR
36 LifeMap
38 LOVD
40 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
52 NINDS
53 Novoseek
55 ODiseA
56 OMIM via Orphanet
57 OMIM® (Updated 08-Dec-2022)
61 PubChem
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 Tocris
71 UMLS
72 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....